RU2009115364A - Антагонисты рецепторов для лечения метастатического рака - Google Patents
Антагонисты рецепторов для лечения метастатического рака Download PDFInfo
- Publication number
- RU2009115364A RU2009115364A RU2009115364/15A RU2009115364A RU2009115364A RU 2009115364 A RU2009115364 A RU 2009115364A RU 2009115364/15 A RU2009115364/15 A RU 2009115364/15A RU 2009115364 A RU2009115364 A RU 2009115364A RU 2009115364 A RU2009115364 A RU 2009115364A
- Authority
- RU
- Russia
- Prior art keywords
- pdgfrα
- antibody
- tumor
- antagonist
- growth
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title claims 2
- 229940044551 receptor antagonist Drugs 0.000 title claims 2
- 208000037819 metastatic cancer Diseases 0.000 title 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 46
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims abstract 27
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims abstract 27
- 239000005557 antagonist Substances 0.000 claims abstract 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 10
- 208000018084 Bone neoplasm Diseases 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 8
- 230000004614 tumor growth Effects 0.000 claims abstract 6
- 239000003098 androgen Substances 0.000 claims abstract 4
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- 230000003834 intracellular effect Effects 0.000 claims abstract 4
- 210000004881 tumor cell Anatomy 0.000 claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 230000001419 dependent effect Effects 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 239000003102 growth factor Substances 0.000 claims abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002411 imatinib Drugs 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 201000005202 lung cancer Diseases 0.000 claims abstract 2
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 2
- 208000011581 secondary neoplasm Diseases 0.000 claims abstract 2
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ лечения субъекта, имеющего опухоль кости, который включает введение эффективного количества антагониста PDGFRα. ! 2. Способ ингибирования роста опухоли кости, который включает введение эффективного количества антагониста PDGFRα. ! 3. Способ по п. 1 или 2, где опухоль кости представляет собой первичную опухоль. ! 4. Способ по п. 1 или 2, где опухоль кости представляет собой вторичную опухоль. ! 5. Способ по п. 1 или 2, где рост опухолевых клеток является андроген-зависимым. ! 6. Способ по п. 1 или 2, где рост опухолевых клеток является андроген-независимым. ! 7. Способ по п. 1 или 2, где опухоль метастазирует из рака предстательной железы. ! 8. Способ по п. 1 или 2, где опухоль метастазирует из рака молочной железы. ! 9. Способ по п. 1 или 2, где опухоль метастазирует из рака легких. ! 10. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой антитело или фрагмент антитела. ! 11. Способ по п.10, где антитело или фрагмент антитела конкурирует за связывание с PDGFRα с антителом, включающим тяжелую цепь вариабельного домена, имеющую SEQ ID NO:8, и легкую цепь вариабельного домена, имеющую SEQ ID NO:16. ! 12. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой внутриклеточный ингибитор PDGFRα. ! 13. Способ по п.12, где внутриклеточный ингибитор PDGFRα выбран из группы, состоящей из AG1296, STI-571 и SU11248. ! 14. Способ по п.10, где антитело или фрагмент антитела представляют собой антитело или фрагмент антитела человека. ! 15. Способ по п. 10, где антитело или фрагмент антитела являются гуманизованными. ! 16. Способ по п.10, где антитело или фрагмент антитела является химерным. ! 17. Способ по п. 1 или 2, где антагонист PDGFRα ингибирует связывание тромбоцитарного фактора роста с PDGFRα. !
Claims (29)
1. Способ лечения субъекта, имеющего опухоль кости, который включает введение эффективного количества антагониста PDGFRα.
2. Способ ингибирования роста опухоли кости, который включает введение эффективного количества антагониста PDGFRα.
3. Способ по п. 1 или 2, где опухоль кости представляет собой первичную опухоль.
4. Способ по п. 1 или 2, где опухоль кости представляет собой вторичную опухоль.
5. Способ по п. 1 или 2, где рост опухолевых клеток является андроген-зависимым.
6. Способ по п. 1 или 2, где рост опухолевых клеток является андроген-независимым.
7. Способ по п. 1 или 2, где опухоль метастазирует из рака предстательной железы.
8. Способ по п. 1 или 2, где опухоль метастазирует из рака молочной железы.
9. Способ по п. 1 или 2, где опухоль метастазирует из рака легких.
10. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой антитело или фрагмент антитела.
11. Способ по п.10, где антитело или фрагмент антитела конкурирует за связывание с PDGFRα с антителом, включающим тяжелую цепь вариабельного домена, имеющую SEQ ID NO:8, и легкую цепь вариабельного домена, имеющую SEQ ID NO:16.
12. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой внутриклеточный ингибитор PDGFRα.
13. Способ по п.12, где внутриклеточный ингибитор PDGFRα выбран из группы, состоящей из AG1296, STI-571 и SU11248.
14. Способ по п.10, где антитело или фрагмент антитела представляют собой антитело или фрагмент антитела человека.
15. Способ по п. 10, где антитело или фрагмент антитела являются гуманизованными.
16. Способ по п.10, где антитело или фрагмент антитела является химерным.
17. Способ по п. 1 или 2, где антагонист PDGFRα ингибирует связывание тромбоцитарного фактора роста с PDGFRα.
18. Способ по п. 1 или 2, где антагонист PDGFRα нейтрализует активацию PDGFRα.
19. Способ по п. 1 или 2, где антагонист PDGFRα уменьшает концентрацию поверхностного рецептора PDGFRα.
20. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой антитело, которое связывается с IGF-IR с Kd, составляющей примерно 10-9М-1 или менее.
21. Способ по п. 1 или 2, где антагонист PDGFRα ингибирует фосфорилирование сигнальной молекулы в прямом направлении от PDGFRα.
22. Способ по п. 1 или 2, где антагонист PDGFRα ингибирует активацию Akt, индуцированную костным мозгом.
23. Способ по п. 1 или 2, дополнительно включающий совместное введение второго антагониста рецептора тирозинкиназы.
24. Способ по п. 1 или 2, где антагонист PDGFRα представляет собой биспецифическое антитело.
25. Способ по п.24, где биспецифическое антитело является специфическим в отношении IGF-IR и EGFR.
26. Способ по п. 1 или 2, дополнительно включающий введение эффективного количества противоопухолевого средства.
27. Способ по п. 26, где противоопухолевое средство представляет собой доцетаксел.
28. Способ по п. 26, где противоопухолевое средство представляет собой доксорубицин.
29. Способ по п.26, где противоопухолевое средство представляет собой облучение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69192005P | 2005-06-17 | 2005-06-17 | |
| US60/691,920 | 2005-06-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008101772/14A Division RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009115364A true RU2009115364A (ru) | 2010-10-27 |
| RU2502523C2 RU2502523C2 (ru) | 2013-12-27 |
Family
ID=37571297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009115364/15A RU2502523C2 (ru) | 2005-06-17 | 2006-06-19 | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| RU2008101772/14A RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
| RU2009115363A RU2455026C3 (ru) | 2005-06-17 | 2009-04-22 | Антагонисты рецепторов для лечения метастатического рака |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008101772/14A RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
| RU2009115363A RU2455026C3 (ru) | 2005-06-17 | 2009-04-22 | Антагонисты рецепторов для лечения метастатического рака |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8128929B2 (ru) |
| EP (4) | EP2100618B1 (ru) |
| JP (4) | JP2009501141A (ru) |
| KR (3) | KR101246428B1 (ru) |
| CN (3) | CN101500597A (ru) |
| BR (2) | BRPI0611984A2 (ru) |
| CA (3) | CA2612449A1 (ru) |
| CY (3) | CY1114603T1 (ru) |
| DK (2) | DK2100618T3 (ru) |
| ES (2) | ES2435727T3 (ru) |
| HU (1) | HUS1700015I1 (ru) |
| IL (3) | IL188151A0 (ru) |
| LT (1) | LTC2100614I2 (ru) |
| LU (1) | LUC00012I2 (ru) |
| NL (1) | NL300869I2 (ru) |
| PL (2) | PL2100614T3 (ru) |
| PT (2) | PT2100614E (ru) |
| RU (3) | RU2502523C2 (ru) |
| SI (2) | SI2100618T1 (ru) |
| WO (1) | WO2006138729A2 (ru) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101500597A (zh) * | 2005-06-17 | 2009-08-05 | 伊姆克罗尼系统公司 | 治疗转移性骨癌的受体拮抗剂 |
| KR101353706B1 (ko) * | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제 |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| US8435510B2 (en) | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
| US20090280112A1 (en) * | 2008-05-05 | 2009-11-12 | The Regents Of The University Of California | Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
| HRP20150963T4 (hr) | 2010-06-07 | 2023-12-08 | Amgen Inc. | Uređaj za primjenu lijeka |
| JP2013177317A (ja) * | 2010-06-24 | 2013-09-09 | Meneki Seibutsu Kenkyusho:Kk | 抗ｐｄｇｆ受容体抗体 |
| CA2803998A1 (en) * | 2010-07-02 | 2012-01-05 | Medimmune, Llc | Antibody formulations |
| EP2671082B1 (en) | 2011-02-02 | 2020-01-15 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
| CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
| CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| SMT201800287T1 (it) | 2011-10-14 | 2018-07-17 | Amgen Inc | Iniettore e metodo di assiemaggio |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| CA2884887C (en) | 2012-11-21 | 2023-09-12 | Amgen Inc. | Drug delivery device including insertion member and reservoir |
| CA2941010A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
| US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
| KR102295834B1 (ko) | 2013-03-15 | 2021-08-30 | 암젠 인크 | 인체 윤곽 적응성을 가진 자기 주사기 장치 |
| EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| WO2014143815A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| CA2897825C (en) | 2013-03-22 | 2022-05-24 | Scott R. Gibson | Injector and method of assembly |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| MX373358B (es) | 2013-10-24 | 2020-07-06 | Amgen Inc | Inyector y método de montaje. |
| MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
| CN106029150B (zh) * | 2013-12-20 | 2020-01-14 | 波士顿科学国际有限公司 | 集成导管系统 |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| MX388536B (es) | 2014-05-07 | 2025-03-20 | Amgen Inc | Autoinyector con elementos reductores del shock. |
| WO2015187805A2 (en) | 2014-06-03 | 2015-12-10 | Amgen Inc. | Systems and methods for supporting patient use of a drug delivery device |
| AP2016009649A0 (en) | 2014-07-03 | 2016-12-31 | Imclone Llc | Combination therapy |
| EP3164416A1 (en) | 2014-07-03 | 2017-05-10 | Imclone, LLC | Therapy for gist |
| EP3206739B1 (en) | 2014-10-14 | 2021-12-01 | Amgen Inc. | Drug injection device with visual and audio indicators |
| SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| ES2898469T3 (es) | 2014-12-19 | 2022-03-07 | Amgen Inc | Dispositivo de administración de medicamentos con sensor de proximidad |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
| IL302211A (en) | 2015-12-16 | 2023-06-01 | Regeneron Pharma | Preparations and methods for making protein microparticles |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| EP4035711B1 (en) | 2016-03-15 | 2025-06-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| EP3455142B1 (en) | 2016-05-13 | 2023-08-09 | Amgen Inc. | Vial sleeve assembly |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| EP3478342B1 (en) | 2016-07-01 | 2025-03-12 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| ES2822084T3 (es) * | 2016-07-28 | 2021-04-29 | Elanco Us Inc | Anticuerpo antirreceptor alfa del factor de crecimiento derivado de plaquetas canino |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| KR102014066B1 (ko) | 2017-01-06 | 2019-10-21 | 에이비엘바이오 주식회사 | 항 α-syn 항체 및 그 용도 |
| JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
| MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
| AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
| MX2019010544A (es) | 2017-03-06 | 2019-10-21 | Amgen Inc | Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion. |
| SG11201908058UA (en) | 2017-03-07 | 2019-09-27 | Amgen Inc | Needle insertion by overpressure |
| AU2018230486B2 (en) | 2017-03-09 | 2023-05-11 | Amgen Inc. | Insertion mechanism for drug delivery device |
| US20200071415A1 (en) | 2017-03-17 | 2020-03-05 | Imclone Llc | Combination therapy for pancreatic cancer |
| PT3600491T (pt) | 2017-03-28 | 2023-10-18 | Amgen Inc | Sistema e método de haste de êmbolo e conjunto de seringa |
| AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| WO2018226565A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| CA3063920A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | Device activation impact/shock reduction |
| EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
| IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing member for drug container and methods of assembly |
| WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
| MA49677A (fr) | 2017-07-25 | 2021-04-21 | Amgen Inc | Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé |
| MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
| EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| WO2019070497A1 (en) | 2017-10-04 | 2019-04-11 | Imclone Llc | POLY THERAPY AGAINST CANCER |
| US11759565B2 (en) | 2017-10-04 | 2023-09-19 | Amgen Inc. | Flow adapter for drug delivery device |
| IL272636B2 (en) | 2017-10-06 | 2024-10-01 | Amgen Inc | Drug delivery device with interlock assembly and related method of assembly |
| US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| IL273663B2 (en) | 2017-11-03 | 2025-05-01 | Amgen Inc | System and methods for disinfecting a drug delivery device |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| CN111263651B (zh) | 2017-11-16 | 2022-06-17 | 安进公司 | 具有停顿和终点检测的自动注射器 |
| MX2020004996A (es) | 2017-11-16 | 2020-08-27 | Amgen Inc | Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos. |
| CN116731173A (zh) | 2017-12-14 | 2023-09-12 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| WO2019231803A1 (en) | 2018-05-31 | 2019-12-05 | Imclone Llc | Combination therapy for soft tissue sarcoma |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| JP2022500095A (ja) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | インターベンション投薬システム及び方法 |
| CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| CN117159846A (zh) | 2018-10-02 | 2023-12-05 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
| CA3112214A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
| SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
| EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CN109134655B (zh) * | 2018-11-28 | 2019-02-26 | 上海复宏汉霖生物技术股份有限公司 | 一种抗PDGFRα的单克隆抗体及其制备方法和应用 |
| ES3032751T3 (en) | 2019-04-24 | 2025-07-24 | Amgen Inc | Syringe sterilization verification assemblies and methods |
| EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
| MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
| JP7769388B2 (ja) | 2019-12-12 | 2025-11-13 | ティン セラピューティクス，インコーポレイテッド | 聴覚損失の予防及び治療のための組成物及び方法 |
| EP4308599A1 (en) * | 2021-03-19 | 2024-01-24 | Eli Lilly and Company | Methods of treating cancer with pdgfr alpha inhibitors |
| WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| AU2023442603A1 (en) * | 2023-04-04 | 2025-09-11 | Eli Lilly And Company | Reagents and methods for imaging cancers expressing pdgfralpha |
| WO2024207069A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Reagents and methods for imaging cancers expressing pdgfralpha |
| WO2024207047A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Methods of treating cancers expressing pdgfralpha |
| WO2024207070A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Methods of treating cancers expressing pdgfralpha |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4774321A (en) | 1986-12-01 | 1988-09-27 | Massachusetts Institute Of Technology | DP100 EGF and insulin-binding protein from Drosophila cells |
| ATE90690T1 (de) | 1987-04-06 | 1993-07-15 | Celtrix Pharma | Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung. |
| US5200509A (en) | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| WO1989009825A1 (en) | 1988-04-16 | 1989-10-19 | Celltech Limited | Method for producing recombinant dna proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| US6228600B1 (en) | 1992-07-20 | 2001-05-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunoassays for the alpha platelet-derived growth factor receptor |
| US7252929B2 (en) | 1989-02-09 | 2007-08-07 | United States Of America, As Represented By The Secretary, Dept Of Health & Human Services | Methods for identifying alpha PDGFR agonists and antagonists |
| DE69034254D1 (de) | 1989-02-09 | 2008-07-17 | Us Health | A-pdgf-rezeptor und dessen verwendung |
| US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| WO1991016051A1 (en) | 1990-04-16 | 1991-10-31 | Rhône-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| IE913032A1 (en) | 1990-08-28 | 1992-03-11 | Chiron Corp | New insulin-like growth factor binding protein (igfbp-4) |
| DE69231128T2 (de) | 1991-01-31 | 2001-02-15 | Cor Therapeutics, Inc. | Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5262308A (en) | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
| WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
| US5597563A (en) | 1992-09-04 | 1997-01-28 | Beschorner; William E. | Method induction of antigen-specific immune tolerance |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5620687A (en) | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
| ATE170402T1 (de) | 1993-02-25 | 1998-09-15 | Zymogenetics Inc | Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima |
| US5976534A (en) | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| WO1994023034A2 (en) | 1993-04-06 | 1994-10-13 | Cedars-Sinai Medical Center | Variant insulin-like growth factor i receptor subunits and methods for use thereof |
| CA2179383A1 (en) | 1994-01-14 | 1995-07-20 | Ira D. Goldfine | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
| DE69518919T2 (de) | 1994-06-24 | 2001-03-29 | Leonid Iakoubov | Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung |
| US5939269A (en) | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
| ES2161290T3 (es) | 1995-03-30 | 2001-12-01 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CA2235695A1 (en) | 1995-11-14 | 1997-05-22 | Thomas Jefferson University | Inducing resistance to tumor growth with soluble igf-1 receptor |
| JP4275733B2 (ja) | 1996-01-23 | 2009-06-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジンおよびその製造法 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
| ATE308527T1 (de) | 1996-06-24 | 2005-11-15 | Pfizer | Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten |
| US5798266A (en) | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
| US6071891A (en) | 1996-11-22 | 2000-06-06 | Regents Of The University Of Minnesota | Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition |
| JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン |
| IL139707A0 (en) | 1998-05-15 | 2002-02-10 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| HUP0103520A3 (en) | 1998-09-29 | 2003-01-28 | Wyeth Holdings Corp Madison | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them |
| KR100731820B1 (ko) | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
| EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
| US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| WO2001006967A1 (en) | 1999-07-27 | 2001-02-01 | Michael Miravet Sorribes | A device for non-invasively correcting the shape of a human external ear |
| WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| RU2183461C2 (ru) * | 2000-05-29 | 2002-06-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения сарком мягких тканей |
| US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| AU2001274536A1 (en) | 2000-06-15 | 2002-01-02 | Kyowa Hakko Kogyo Co. Ltd. | Insulin-like growth factor-binding protein |
| US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| DE60141855D1 (de) * | 2001-01-05 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i |
| US7071300B2 (en) | 2001-03-14 | 2006-07-04 | Genentech, Inc. | IGF antagonist peptides |
| US20040116330A1 (en) | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| EP1798242B1 (fr) | 2002-01-18 | 2013-01-23 | Pierre Fabre Medicament | Anticorps anti-IGF-IR et leurs applications |
| US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| ES2362931T3 (es) | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| KR101115797B1 (ko) | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법 |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| JP2006517581A (ja) | 2003-02-13 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗インスリン様増殖因子ｉ受容体抗体の使用 |
| CA2518980A1 (en) | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
| CA2519113C (en) | 2003-04-02 | 2012-06-05 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| CA2524305C (en) * | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| RU2241452C1 (ru) * | 2003-06-11 | 2004-12-10 | Московский областной научно-исследовательский клинический институт | Способ лечения метастазов в кости |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| MXPA06001634A (es) * | 2003-08-13 | 2006-04-28 | Pfizer Prod Inc | Anticuerpos humanos modificados igf-1r. |
| CA2536288A1 (en) | 2003-08-21 | 2005-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Cancer metastasis inhibitor |
| JPWO2005027970A1 (ja) | 2003-09-24 | 2007-11-15 | 協和醗酵工業株式会社 | 癌治療用医薬 |
| AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| ES2368741T3 (es) | 2004-02-25 | 2011-11-21 | Dana-Farber Cancer Institute, Inc. | Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales. |
| WO2005087808A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| JP4493485B2 (ja) | 2004-04-28 | 2010-06-30 | シャープ株式会社 | 太陽電池モジュール用配線部材、それを用いた太陽電池モジュールおよび太陽電池モジュール用配線部材の製造方法 |
| NZ552091A (en) | 2004-07-16 | 2009-09-25 | Pfizer Prod Inc | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| MX2007006640A (es) | 2004-12-03 | 2007-06-19 | Schering Corp | Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina. |
| US20060134172A1 (en) | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| JP2008538365A (ja) | 2005-04-15 | 2008-10-23 | イミュノジェン・インコーポレーテッド | 腫瘍内の不均一または混合細胞集団を排除する方法 |
| CN101500597A (zh) * | 2005-06-17 | 2009-08-05 | 伊姆克罗尼系统公司 | 治疗转移性骨癌的受体拮抗剂 |
| WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| US20070009970A1 (en) | 2005-07-08 | 2007-01-11 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| AR055137A1 (es) | 2005-08-26 | 2007-08-08 | Glycart Biotechnology Ag | Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada |
| ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
| WO2010000008A1 (en) | 2008-06-30 | 2010-01-07 | Desi Raymond Richardson | Thiosemicarbazone compounds and use thereof |
| JP5341187B2 (ja) | 2008-07-18 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なフェニルイミダゾピラジン類 |
| DK200900548A (en) | 2008-07-18 | 2010-01-19 | Univ Koebenhavn | Processes for manufacture of products from plants |
-
2006
- 2006-06-19 CN CNA2006800284670A patent/CN101500597A/zh active Pending
- 2006-06-19 DK DK09075102.5T patent/DK2100618T3/en active
- 2006-06-19 BR BRPI0611984-0A patent/BRPI0611984A2/pt not_active IP Right Cessation
- 2006-06-19 KR KR1020097003170A patent/KR101246428B1/ko not_active Expired - Fee Related
- 2006-06-19 PT PT90751033T patent/PT2100614E/pt unknown
- 2006-06-19 CA CA002612449A patent/CA2612449A1/en not_active Abandoned
- 2006-06-19 PT PT90751025T patent/PT2100618E/pt unknown
- 2006-06-19 RU RU2009115364/15A patent/RU2502523C2/ru not_active IP Right Cessation
- 2006-06-19 DK DK09075103.3T patent/DK2100614T3/da active
- 2006-06-19 EP EP09075102.5A patent/EP2100618B1/en not_active Not-in-force
- 2006-06-19 SI SI200631744T patent/SI2100618T1/sl unknown
- 2006-06-19 US US11/917,890 patent/US8128929B2/en active Active
- 2006-06-19 WO PCT/US2006/023856 patent/WO2006138729A2/en not_active Ceased
- 2006-06-19 ES ES09075103T patent/ES2435727T3/es active Active
- 2006-06-19 EP EP06785127A patent/EP1909819A4/en not_active Withdrawn
- 2006-06-19 EP EP12162951A patent/EP2505205A1/en not_active Withdrawn
- 2006-06-19 CA CA2680945A patent/CA2680945C/en active Active
- 2006-06-19 RU RU2008101772/14A patent/RU2008101772A/ru not_active Application Discontinuation
- 2006-06-19 EP EP09075103.3A patent/EP2100614B8/en active Active
- 2006-06-19 CN CN200910126431.1A patent/CN101613409B/zh active Active
- 2006-06-19 BR BRPI0622073A patent/BRPI0622073A8/pt not_active Application Discontinuation
- 2006-06-19 PL PL09075103T patent/PL2100614T3/pl unknown
- 2006-06-19 CN CN2009101264326A patent/CN101612399B/zh not_active Expired - Fee Related
- 2006-06-19 JP JP2008517219A patent/JP2009501141A/ja active Pending
- 2006-06-19 PL PL09075102T patent/PL2100618T3/pl unknown
- 2006-06-19 SI SI200631722T patent/SI2100614T1/sl unknown
- 2006-06-19 ES ES09075102.5T patent/ES2452115T3/es active Active
- 2006-06-19 CA CA2678008A patent/CA2678008C/en not_active Expired - Fee Related
- 2006-06-19 KR KR1020087001415A patent/KR20080047529A/ko not_active Withdrawn
- 2006-06-19 KR KR1020097003171A patent/KR101246504B1/ko active Active
-
2007
- 2007-12-16 IL IL188151A patent/IL188151A0/en unknown
-
2009
- 2009-02-17 JP JP2009033512A patent/JP5154470B2/ja not_active Expired - Fee Related
- 2009-02-17 JP JP2009033517A patent/JP5436883B2/ja active Active
- 2009-04-22 RU RU2009115363A patent/RU2455026C3/ru active Protection Beyond IP Right Term
- 2009-05-21 IL IL198870A patent/IL198870A/en active Protection Beyond IP Right Term
- 2009-05-21 IL IL198869A patent/IL198869A/en not_active IP Right Cessation
-
2011
- 2011-10-19 US US13/276,358 patent/US8425911B2/en not_active Expired - Fee Related
- 2011-10-19 US US13/276,353 patent/US8574578B2/en active Active
-
2012
- 2012-06-13 JP JP2012134040A patent/JP2012179060A/ja active Pending
-
2013
- 2013-11-14 CY CY20131101013T patent/CY1114603T1/el unknown
-
2014
- 2014-04-04 CY CY20141100261T patent/CY1115076T1/el unknown
-
2017
- 2017-04-05 CY CY2017013C patent/CY2017013I1/el unknown
- 2017-04-05 LU LU00012C patent/LUC00012I2/fr unknown
- 2017-04-14 NL NL300869C patent/NL300869I2/nl unknown
- 2017-04-18 HU HUS1700015C patent/HUS1700015I1/hu unknown
- 2017-04-18 LT LTPA2017011C patent/LTC2100614I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009115364A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| RU2349340C2 (ru) | Биспецифические антитела к erb-b и их применение для лечения опухолей | |
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| RU2012117619A (ru) | ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3 | |
| Lynch et al. | Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment | |
| WO2009106321A1 (en) | Treatment of resistant tumors with trifunctional antibodies | |
| WO2007145862B1 (en) | Extending survival of cancer patients with elevated levels of egf or tgf-alpha | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2007125644A (ru) | Отбор пациентов для терапии ингибитором her | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| RU2006139073A (ru) | Способы лечения боли, обусловленной раком кости, путем введения антагониста фактора роста нервов | |
| JP2009501141A5 (ja) | 骨腫瘍の治療のための抗igf-ir抗体 | |
| UA89350C2 (ru) | Гуманизированое антитело, которое связывает человеческий cd20 | |
| JP2008531576A5 (ru) | ||
| US9822170B2 (en) | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer | |
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
| FI3665198T3 (fi) | EGFR:ää ja cMET:tä sitovia vasta-aineita | |
| CY1113260T1 (el) | ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΡΚΙΝΟΥ ME TO ANTI-ErbB2 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΜΟΝΟΚΛΩΝΙΚΟ ΑΝΤΙΣΩΜΑ 2C4 (rhuMab 2C4) | |
| EA201170157A1 (ru) | Notch-связывающие агенты и антагонисты и способы их применения | |
| RU2008121901A (ru) | Применения антител против cd40 | |
| AR077241A1 (es) | Metodo de tratamiento del cancer conantagonista dll4 y agente quimioterapeutico | |
| RU2014134923A (ru) | Антагонисты alk1 и их применение в лечении почечно-клеточного рака | |
| EA200870141A1 (ru) | Комбинационная терапия с использованием антител к egfr и her2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200620 |